GlassScriptPhysician profile
Christopher W Swift
NPI 1023320280
$985.99
in general payments reported to CMS, 2019-2025
12 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $59.71 · 2021: $94.78 · 2022: $129 · 2023: $14.16 · 2024: $25.51 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $125.00 | 2025 | Evenity |
| Novo Nordisk INC | $102.80 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $80.96 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.37 | 2022-2024 | |
| Lilly USA, LLC | $48.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.10 | 2019-2021 | |
| Allergan, INC. | $33.58 | 2019 | |
| Insmed, INC. | $29.34 | 2021 | |
| Vapotherm INC | $22.87 | 2019 | |
| Merck Sharp & Dohme LLC | $14.16 | 2023 | Zerbaxa, Recarbrio |
| Mallinckrodt Hospital Products INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Swift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.